Research programme: BACE1 protein inhibitors - De Novo Pharmaceuticals
Alternative Names: DNP 004089Latest Information Update: 19 Jan 2011
At a glance
- Originator De Novo Pharmaceuticals
- Class Small molecules
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 23 Feb 2004 This programme is available for licensing (http://www.denovopharma.com)
- 21 Jan 2004 Preclinical trials in Alzheimer's disease in USA (unspecified route)